These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 23623503)

  • 1. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies.
    Adão R; de Keulenaer G; Leite-Moreira A; Brás-Silva C
    Rev Port Cardiol; 2013 May; 32(5):395-409. PubMed ID: 23623503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity and cardioprotection in childhood cancer.
    Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
    Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer therapy induced cardiotoxicity: review of the literature.
    Geiger S; Lange V; Suhl P; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2010 Jul; 21(6):578-90. PubMed ID: 20375725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
    Nelson-Veniard M; Thambo JB
    Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
    Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
    CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardioprotective treatment during adjuvant cancer therapy].
    Gulati G; Heck SL; Ree AH; Gravdehaug B; Røsjø H; Steine K; Bratland Å; Hoffmann P; Geisler J; Omland T
    Tidsskr Nor Laegeforen; 2013 Sep; 133(17):1832-6. PubMed ID: 24042297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced cardiotoxicity: detection, prevention, and management.
    Truong J; Yan AT; Cramarossa G; Chan KK
    Can J Cardiol; 2014 Aug; 30(8):869-78. PubMed ID: 25064580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Popat S; Smith IE
    Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity of systemic agents used in breast cancer.
    Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
    Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.
    Rochette L; Guenancia C; Gudjoncik A; Hachet O; Zeller M; Cottin Y; Vergely C
    Trends Pharmacol Sci; 2015 Jun; 36(6):326-48. PubMed ID: 25895646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy.
    Zuppinger C; Timolati F; Suter TM
    Cardiovasc Toxicol; 2007; 7(2):61-6. PubMed ID: 17652805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer agents and cardiotoxicity.
    Ng R; Better N; Green MD
    Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.
    Zerra P; Cochran TR; Franco VI; Lipshultz SE
    Expert Opin Pharmacother; 2013 Aug; 14(11):1497-513. PubMed ID: 23705955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and Treatment of Cardiac Dysfunction in Breast Cancer Survivors.
    Fabian C
    Adv Exp Med Biol; 2015; 862():213-30. PubMed ID: 26059938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity of cancer chemotherapy: implications for children.
    Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE
    Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
    Yeh ET; Tong AT; Lenihan DJ; Yusuf SW; Swafford J; Champion C; Durand JB; Gibbs H; Zafarmand AA; Ewer MS
    Circulation; 2004 Jun; 109(25):3122-31. PubMed ID: 15226229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads.
    Sengupta PP; Northfelt DW; Gentile F; Zamorano JL; Khandheria BK
    Mayo Clin Proc; 2008 Feb; 83(2):197-203. PubMed ID: 18241629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity.
    de Geus-Oei LF; Mavinkurve-Groothuis AM; Bellersen L; Gotthardt M; Oyen WJ; Kapusta L; van Laarhoven HW
    J Nucl Med; 2011 Apr; 52(4):560-71. PubMed ID: 21421717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.